139 related articles for article (PubMed ID: 25612805)
1. A novel inhaled multi-pronged attack against respiratory bacteria.
Lee SH; Teo J; Heng D; Zhao Y; Ng WK; Chan HK; Tan LT; Tan RB
Eur J Pharm Sci; 2015 Apr; 70():37-44. PubMed ID: 25612805
[TBL] [Abstract][Full Text] [Related]
2. Synergistic combination dry powders for inhaled antimicrobial therapy: formulation, characterization and in vitro evaluation.
Lee SH; Teo J; Heng D; Ng WK; Chan HK; Tan RB
Eur J Pharm Biopharm; 2013 Feb; 83(2):275-84. PubMed ID: 23010564
[TBL] [Abstract][Full Text] [Related]
3. Tailored Antibiotic Combination Powders for Inhaled Rotational Antibiotic Therapy.
Lee SH; Teo J; Heng D; Ng WK; Zhao Y; Tan RB
J Pharm Sci; 2016 Apr; 105(4):1501-12. PubMed ID: 27019964
[TBL] [Abstract][Full Text] [Related]
4. Steroid-decorated antibiotic microparticles for inhaled anti-infective therapy.
Lee SH; Teo J; Heng D; Zhao Y; Ng WK; Chan HK; Tan RB
J Pharm Sci; 2014 Apr; 103(4):1115-25. PubMed ID: 24510431
[TBL] [Abstract][Full Text] [Related]
5. Inhaled mucoactive particles with tailored architecture for enhanced aerodynamicity, stability and efficacy.
Lee SH; Heng D; Teo JWP; Toh FKY; Tan RBH
Int J Pharm; 2019 Dec; 572():118740. PubMed ID: 31648015
[TBL] [Abstract][Full Text] [Related]
6. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
Zhou QT; Sun SP; Chan JG; Wang P; Barraud N; Rice SA; Wang J; Li J; Chan HK
Mol Pharm; 2015 Aug; 12(8):2594-603. PubMed ID: 25423590
[TBL] [Abstract][Full Text] [Related]
7. Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Lin Y; Chang RYK; Britton WJ; Morales S; Kutter E; Li J; Chan HK
Eur J Pharm Biopharm; 2019 Sep; 142():543-552. PubMed ID: 31398437
[TBL] [Abstract][Full Text] [Related]
8. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
[TBL] [Abstract][Full Text] [Related]
9. Cospray dried antibiotics for dry powder lung delivery.
Adi H; Young PM; Chan HK; Stewart P; Agus H; Traini D
J Pharm Sci; 2008 Aug; 97(8):3356-66. PubMed ID: 17990305
[TBL] [Abstract][Full Text] [Related]
10. In vivo efficacy of a dry powder formulation of ciprofloxacin-copper complex in a chronic lung infection model of bioluminescent Pseudomonas aeruginosa.
Tewes F; Bahamondez-Canas TF; Moraga-Espinoza D; Smyth HDC; Watts AB
Eur J Pharm Biopharm; 2020 Jul; 152():210-217. PubMed ID: 32442738
[TBL] [Abstract][Full Text] [Related]
11. The Delivery of High-Dose Dry Powder Antibiotics by a Low-Cost Generic Inhaler.
Parumasivam T; Leung SS; Tang P; Mauro C; Britton W; Chan HK
AAPS J; 2017 Jan; 19(1):191-202. PubMed ID: 27679516
[TBL] [Abstract][Full Text] [Related]
12. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
Adi H; Young PM; Chan HK; Agus H; Traini D
Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286
[TBL] [Abstract][Full Text] [Related]
13. A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart.
Tran TT; Vidaillac C; Yu H; Yong VFL; Roizman D; Chandrasekaran R; Lim AYH; Low TB; Tan GL; Abisheganaden JA; Koh MS; Teo J; Chotirmall SH; Hadinoto K
Int J Pharm; 2018 Aug; 547(1-2):368-376. PubMed ID: 29886096
[TBL] [Abstract][Full Text] [Related]
14. Development and characterization of a spray-dried inhalable ternary combination for the treatment of Pseudomonas aeruginosa biofilm infection in cystic fibrosis.
Alhajj N; Yahya MFZR; O'Reilly NJ; Cathcart H
Eur J Pharm Sci; 2024 Jan; 192():106654. PubMed ID: 38013123
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
[TBL] [Abstract][Full Text] [Related]
16. Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. Aeruginosa biofilm eradication.
Wang J; Guo Y; Lu W; Liu X; Zhang J; Sun J; Chai G
Int J Pharm; 2024 Jun; 658():124208. PubMed ID: 38723731
[TBL] [Abstract][Full Text] [Related]
17. Dry powder inhaler formulation of high-payload antibiotic nanoparticle complex intended for bronchiectasis therapy: Spray drying versus spray freeze drying preparation.
Yu H; Teo J; Chew JW; Hadinoto K
Int J Pharm; 2016 Feb; 499(1-2):38-46. PubMed ID: 26757148
[TBL] [Abstract][Full Text] [Related]
18. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
Stass H; Delesen H; Nagelschmitz J; Staab D
J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
[TBL] [Abstract][Full Text] [Related]
19. Development of inhalable hyaluronan/mannitol composite dry powders for flucytosine repositioning in local therapy of lung infections.
Costabile G; d'Angelo I; d'Emmanuele di Villa Bianca R; Mitidieri E; Pompili B; Del Porto P; Leoni L; Visca P; Miro A; Quaglia F; Imperi F; Sorrentino R; Ungaro F
J Control Release; 2016 Sep; 238():80-91. PubMed ID: 27449745
[TBL] [Abstract][Full Text] [Related]
20. Effects of Surface Composition on the Aerosolisation and Dissolution of Inhaled Antibiotic Combination Powders Consisting of Colistin and Rifampicin.
Wang W; Zhou QT; Sun SP; Denman JA; Gengenbach TR; Barraud N; Rice SA; Li J; Yang M; Chan HK
AAPS J; 2016 Mar; 18(2):372-84. PubMed ID: 26603890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
